UNSPSC 51182223: Oxytocin citrate

This classification denotes a pituitary hormone C43H66N12O12S2.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1573L6WJ8U, chemically known as oxytocin, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt), but more generally known as oxytocin citrate, which bears US NIH Compound Identifier 72941595. European Medicines Agency schedules Oxytocin citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23136.

UNSPSC 51182223 Oxytocin citrate is a Commodity code representing pharmaceutical products that state and local health systems and purchasing cooperatives procure through multi-source generic and branded supply agreements. State and local governments buy oxytocin citrate primarily as a critical obstetric and uterotonic medication distributed through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and institutional buyers, including hospitals, clinics, and correctional facilities within state and local systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing vehicle for pharmaceutical procurement under this code. MMCAP issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. Vendors must supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and meet strict regulatory compliance including current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) certification. Pricing is weighted at 75 percent of evaluation criteria, with fixed pricing, administrative fee compliance, EDI capability, and price flexibility options (flat price, net price formats, or WAC-minus structures) rated at 25 percent combined. Awarded vendors must carry $5 million commercial general liability, $2 million network security and privacy liability, and $2 million professional liability insurance, with products requiring FDA compliance, one-year minimum expiration dates from manufacture, and six-month minimum shelf life. The resulting contracts are effective July 1, 2026, for a two-year initial term with optional extensions at MMCAP's discretion, subject to a 3 percent administrative fee on all purchases and performance penalties of $200 to $1,500 per violation.